2014 Annual Report

Our guidance range reflects continued confidence in the growth of AMPYRA, increasing from $366.2 million in net sales from 2014.

CVT-301, dalfampridine in chronic post-stroke walking deficits (PSWD) and PLUMIAZ.

Acorda has 5 clinical-stage programs that have potential to improve the lives of millions of patients and drive shareholder value.

We place a high priority on managing SG&A; our guidance represents a minimal increase over 2014 despite added infrastructure related to the Civitas acquisition.